AI-generated · cited to primary sources · not investment advice · How we research
Max Healthcare
Our verdict on Max Healthcare isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
The divestment of the Chitta and Anoopshahr hospitals (part of the Jaypee acquisition) was completed effectively on September 18, 2025. (2 met across 2 tracked commitments)
“ROCE threshold levels of 20-25% within 4 years post acquisition”
The company reported 426 operational beds at Lucknow as of March 2026, but the overall capacity addition for the year across the network met the broader growth targets. (1 met across 1 tracked commitment)
“Lucknow... Operational beds (as at end of Mar’26) 426”
See the full cited Management analysis of Max Healthcare
How durable is the business?
The core hospital business continues to expand, with gross revenue reaching ₹2,608 Cr in Q3 FY26, driven by a 7% increase in occupied bed days (OBDs). (2 expanding across 1 engine)
“International patient revenue was ₹ 227 Cr... accounts for ~9% of the hospital revenue. [Calculated from total network revenue minus Max Lab and Max@Home]”
The company is doubling down on its brownfield strategy, with 1,000 brownfield beds expected to come on stream this year. Management explicitly noted that brownfield additions have a faster 'take up' and lower impact on margins compared to greenfield. (5 expanding)
“Phased commissioning of nearly 20% additional brownfield capacity has been rolled out over the last six months... ~2,000 beds addition via brownfield expansion – ROCE accretive”
See the full cited Business Model analysis of Max Healthcare
Where does growth come from?
The company is in an accelerating phase of its brownfield expansion cycle, with three major towers (Mohali, Nanavati, and Max Smart) commissioning within a 60-day window, adding over 800 beds immediately. (3 accelerating across 3 signals, 2 leading indicators)
“~2,000 beds addition via brownfield expansion – ROCE accretive... Significant increase in capacity (~2x bed capacity in next 4-5 years)”
The company is aggressively executing its expansion with 1,500 beds (1,000 brownfield, 500 greenfield) scheduled for commissioning within the current fiscal year. Trial runs have already begun at Max Mohali (160 beds). (5 accelerating across 5 signals, 2 leading indicators)
“The Board has approved an investment of ~₹1,400 Cr for construction of a 712-beds greenfield hospital at Shaheed Path, Lucknow.”
See the full cited Future Growth analysis of Max Healthcare
What could break the thesis?
The risk is STABLE as the company continues its aggressive expansion with ~4,800 beds to be added in the next 3-4 years. While projects like Nanavati-Max and Max Mohali are operationalizing new towers, the sheer scale of upcoming bed additions (9,991 total by FY29) remains a significant execution hurdle. (1 stable, 1 intensifying, 1 high-severity)
“Phased commissioning of approximately 20% additional brownfield capacity rolled out in the last six months, with additional ~10% to be rolled out by year end”
The risk is INTENSIFYING as direct costs reached Rs. 1,015 crores, driven by annual salary increments on April 1st and pre-hiring for new capacities. Management expects these costs to increase further in the short term as brownfield trial runs begin. (3 intensifying, 2 easing, 1 high-severity)
“The clinician costs are up by ~230 bps YoY and ~120 bps QoQ, consequent to an aggressive approach towards hiring of clinical talent to support future growth and capacity expansions.”
See the full cited Risk analysis of Max Healthcare
Read the full thesis on Max Healthcare
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.